Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) has shared an update.
Haleon PLC has announced changes to its board committees, appointing Bláthnaid Bergin to the Audit & Risk Committee and Matt Shattock to the Environmental & Social Sustainability Committee, effective from July 30, 2025. These appointments are part of Haleon’s ongoing efforts to strengthen its governance and sustainability initiatives, potentially impacting its operational efficiency and stakeholder relations positively.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC’s overall stock score reflects strong financial performance and positive earnings call outlook. Despite some bearish technical indicators and valuation concerns, the company’s strategic initiatives in growth markets and its commitment to shareholder returns provide a positive long-term outlook. Challenges such as market headwinds and inventory adjustments are notable risks.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon is a global leader in consumer health, focusing on delivering better everyday health with humanity. Its product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 23,169,908
Technical Sentiment Signal: Hold
Current Market Cap: £32.7B
See more insights into HLN stock on TipRanks’ Stock Analysis page.